<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="87372">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01941251</url>
  </required_header>
  <id_info>
    <org_study_id>932012</org_study_id>
    <nct_id>NCT01941251</nct_id>
  </id_info>
  <brief_title>Navigated αTMS in Treatment-resistant Schizophrenia</brief_title>
  <acronym>nTMS_NS</acronym>
  <official_title>Navigated Alpha Frequency Transcranial Magnetic Stimulation (αTMS) in Treatment-resistant Schizophrenia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Niuvanniemi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Niuvanniemi Hospital</source>
  <oversight_info>
    <authority>Finland: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Since 1990s, stimulation of prefrontal cortex (PFC) has shown therapeutic effects on
      auditory hallucinations as well as negative symptoms of schizophrenia. However, previous
      studies have reported mixed or negative results. Majority of the repetitive transcranial
      magnetic stimulation (rTMS) studies to date has set the target of cortical stimulation based
      on scalp site. Recently introduced method, navigated transcranial magnetic stimulation
      (nTMS) integrates the individual MRI data, and thus allows more precise targeting on brain
      cortical regions enhancing the efficacy of rTMS. Previous EEG studies have suggested reduced
      alpha band activity in patients with schizophrenia. Some recent studies using alpha (α) EEG
      guided TMS for treating positive and negative symptoms of schizophrenia have demonstrated
      promising results.

      The aim of the study is to investigate the efficacy of navigated individualized αTMS in
      treatment-resistant patients with schizophrenia.  Approximately fifty patients with DSM-IV
      schizophrenia will be enrolled in this randomized, double-blind, sham-controlled study. The
      patients will receive 13 - 15 session of αTMS to the left dorsolateral prefrontal cortex
      (DLPFC), as adjunctive therapy, for 3 weeks.  We assess patients via the Positive and
      Negative Syndrome Scale (PANSS), Clinical Global Impression (CGI) and neurocognitive test
      battery at baseline, 5 days after and 3 months after treatment. Serum and plasma levels of
      brain derived neurotrophic factor (BDNF) are assayed at pre and post treatment weeks.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>at baseline,5 days after treatment, 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in PANSS total sum score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) negative sum score</measure>
    <time_frame>at baseline, 5 days after treatment, 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in PANSS negative sum score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Positive and Negative Syndrome Scale (PANSS) positive sum score</measure>
    <time_frame>at baseline, 5 days after treatment, 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in PANSS positive sum score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Global Impression - Improvement scale (CGI-I)</measure>
    <time_frame>at 5 days after treatment, 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in patient's illness relative to baseline state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neuropsychology test battery</measure>
    <time_frame>at baseline, 5 days after  treatment, 3 months after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Neuropsychology test battery consists of 6 tests for measuring neurocognitive function.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>plasma and serum levels of Brain Derived Neurotrophic Factor (P-/S-BDNF)</measure>
    <time_frame>at baseline, 1 week after treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>change in P-/S-BDNF levels</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Navigated individualized  αTMS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Sham TMS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>navigated Transcranial Magnetic Stimulation</intervention_name>
    <description>individualized α frequency
left DLPFC 110% motor threshold (MT)
13-15 sessions for 3 weeks</description>
    <arm_group_label>Navigated individualized  αTMS</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>navigated Transcranial Magnetic Stimulation</intervention_name>
    <description>- placebo treatment: sham coil</description>
    <arm_group_label>Sham TMS</arm_group_label>
    <other_name>TMS</other_name>
    <other_name>rTMS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male righthanded inpatients, 18 to 64 years of age

          -  The diagnosis of Schizophrenia or Schizoaffective Disorder according to DSM-IV

          -  Capacity and willingness to give informed consent

          -  Patient is treatment-resistant, CGI-S 4 or more

          -  Patient is not requiring a change in antipsychotic medication 2 weeks prior to or
             during treatment

          -  No foreseeable changes in patient's smoking habits during treatment

        Exclusion Criteria:

          -  Serious somatic illness

          -  Progressive neurological illness, recent brain damage (less than 3 months ago) or
             sequela of serious brain damage

          -  Unstable epilepsy

          -  Electro convulsive therapy (ECT) less than 3 months prior to treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Heli Tuppurainen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Niuvanniemi Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Heli Tuppurainen, MD, PhD</last_name>
    <phone>+358 295 242 375</phone>
    <email>heli.tuppurainen@niuva.fi</email>
  </overall_contact>
  <location>
    <facility>
      <name>Niuvanniemi Hospital</name>
      <address>
        <city>Kuopio</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heli Tuppurainen, MD, PhD</last_name>
      <phone>+358 295 242 375</phone>
      <email>heli.tuppurainen@niuva.fi</email>
    </contact>
    <investigator>
      <last_name>Heli Tuppurainen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 12, 2013</lastchanged_date>
  <firstreceived_date>September 9, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Niuvanniemi Hospital</investigator_affiliation>
    <investigator_full_name>Heli Tuppurainen</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Transcranial Magnetic Stimulation</keyword>
  <keyword>Repetitive Transcranial Magnetic Stimulation</keyword>
  <keyword>Schizophrenia</keyword>
  <keyword>Schizoaffective Disorder</keyword>
  <keyword>Treatment</keyword>
  <keyword>Negative Symptoms</keyword>
  <keyword>Positive Symptoms</keyword>
  <keyword>TMS</keyword>
  <keyword>rTMS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psychotic Disorders</mesh_term>
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
